Turn on more accessible mode

Turn off more accessible mode

Skip Ribbon Commands

Skip to main content

Turn off Animations

Turn on Animations

Focus on Content

Leukaemia | Research | CRM | The Aga Khan University

Cell and Peptide-based Therapy for Ph+ Leukaemia

Principal Investigator: Dr Afsar Mian, Assistant Professor

Co-PI: Dr Hammad Hassan, Assistant Professor

Dr Afsar Mian and Dr Hammad Hassan are working on developing novel drugs and treatment approaches for treatment-resistant Leukaemia, a type of blood cancer. Their current focus is on designing a cell and peptide-based method for treating Philadelphia-positive Leukaemia. It is expected that, unlike the existing treatment methods, the new therapy wouldn't require repetitive administration, hence, reducing treatment cost and drug manipulation risks.

The specific objectives of this research are:

Developing the treatment-resistant Leukaemia model
Investigating the mechanisms of drug resistance which results in disease relapse
Developing novel compounds for targetted treatment

Related Publications

Mian AA, Zafar U, Ahmed MA, Ottmann OG, Lalani E-N (2021). Oncogene-Independent Resistance in Philadelphia Chromosome-positive (Ph +) Acute Lymphoblastic Leukaemia (ALL) is Mediated by Activation of AKT/mTOR Pathway. Neoplasia. 2021; Pages 1016-1027; ISSN 1476-5586. doi.org/10.1016/j.neo.2021.07.009.

Mian AA, Baumann I, Liebermann M, Grebien F, Superti-Furga G, Ruthardt M, Ottmann OG and Hantschel O (2019). The Phosphatase UBASH3B/Sts-1 Is a Negative Regulator of BCR-ABL Kinase Activity and Leukemogenesis. Leukaemia. 2019; 33(9): 2319–2323.doi: 10.1038/s41375-019-0468-y.

Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, . . . Ruthardt M (2015). PF-114, a Potent and Selective Inhibitor of Native and Mutated BCR/ABL Is Active Against Philadelphia Chromosome-Positive (Ph+) Leukaemias Harboring the T315I Mutation. Leukaemia, 29(5), 1104-1114. doi:10.1038/leu.2014.326.

Mian AA, Oancea C, Zhao Z, Ottmann OG and Ruthardt M (2009). Oligomerization Inhibition, Combined with Allosteric Inhibition, Abrogates the Transformation Potential of T315I-Positive BCR/ABL. Leukaemia, 23(12), 2242-2247. doi:10.1038/leu.2009.194.

More Publications >>

Principal Investigator

Dr Afsar Mian

Assistant Professor

+92 21 3486 5542

2 Email Logo.png afsar.mian@aku.edu

Related News

AKU wins Rs14.5m HEC grant to develop stem-cell treatments

This grant will support researchers at AKU-CRM to explore the potential of stem cell treatment for a common form of leukaemia.